Company Information

  

Address: 110 ALLEN ROAD
SECOND FLOOR 
City: BASKING RIDGE 
State: NJ 
Zip Code: 07920 
Telephone: 908-842-0100 

Description of Business

Primary SIC Code: 8090
(As filed with the SEC)  

Caladrius Biosciences, Inc. ("we," "us," "our," "Caladrius" or the "Company") is a company developing cellular therapeutics to treat certain diseases. We leverage specialized development expertise to selectively advance therapeutic product candidates to their next significant development milestone and, if appropriate, partner such candidates. Our most advanced product candidate, CLBS03, is an autologous polyclonal regulatory T cell ("Treg") clinical phase 2 therapy targeting children aged 8-17 with recent-onset type 1 diabetes mellitus ("T1D"). We also have phase 2 studies either underway or due to commence shortly involving our CD34 cell therapy for ischemic repair. Immunomodulation (Treg Technology) We are developing strategically, through the utilization of our core development expertise, a product candidate (CLBS03) that has the potential to be an innovative therapy for T1D. This therapy is based on a proprietary platform technology for immunomodulation.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.52NAN/E
12/2017-1.78NAN/E
09/2017-2.13NAN/E
06/2017-2.66NAN/E
03/2017-4.02NAN/E
12/2016-4.99NAN/E
09/2016-10.75NAN/E
06/2016-112.60NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity0.05Total Liab/Total Assets0.20
Net Inc/Total Assets0.35Total Liab/Inv Cap0.24
Net Inc/Inv Cap0.41Total Liab/Comm Equity0.03
Pretax Inc/Net SalesNAInterest Coverage Ratio-72.32
Net Inc/Net SalesNACurr Debt/Equity0.00
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio6.56
Inventory TurnoverNACurrent Ratio6.56
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.90 2.67 2.94 3.43
Operating Income -5.16 -7.32 -6.13 -7.71
Interest Exp 0.00 0.01 0.01 0.20
Pretax Income -4.98 -7.19 -5.96 -7.91
Other Income 0.18 0.14 0.18 0.00
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -4.98 -2.90 -3.55 38.47

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 53.59 60.08 64.45 64.37
Receivables - Total 0.14 0.23 0.40 0.34
Inventories - Total NA NA NA NA
Total Current Assets 54.53 61.11 65.77 70.41
Net Property, Plant & Equipment 0.18 0.26 0.36 0.43
Total Assets 56.72 63.38 67.56 72.25
Liabilities        
Accounts Payable 7.87 9.15 11.02 13.97
Debt in Current Liabilities 0.09 0.16 0.36 0.58
Total Current Liabilities 7.96 9.31 11.37 14.55
Long-Term Debt NA 0.00 0.00 0.02
Total Liabilities 11.13 12.87 14.22 17.83
Stockholder's Equity        
Minority Interest -0.27 -0.32 -0.35 -0.38
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -386.79 -381.81 -378.95 -375.43
Treasury Stock -0.71 -0.71 -0.71 -0.71
Total Stockholders' Equity 45.59 50.51 53.33 54.42
Total Liabilities and Stockholders' Equity 56.72 63.38 67.56 72.25

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -6.30 -3.97 -1.33 -5.49
Net Cash Provided by Investing Activities -1.19 18.23 -3.79 27.00
Net Cash Provided by Financing Activities -0.07 -0.18 2.16 -10.46

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201314.67-38.98--
12/201417.94-54.87--
12/201522.49-80.89--
12/20160.00-33.31-4.99
12/20170.0022.23-1.78
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18307457.79




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.